BIOGEN INC (1BIIB.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BIIB - US09062X1037 - Common Stock
143.15 EUR
+3.8 (+2.73%)
We assign a fundamental rating of 6 out of 10 to 1BIIB. 1BIIB was compared to 78 industry peers in the Biotechnology industry. 1BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. 1BIIB has a bad growth rate and is valued cheaply. These ratings would make 1BIIB suitable for value investing!
1. Profitability
1.1 Basic Checks
1BIIB had positive earnings in the past year.
1BIIB had a positive operating cash flow in the past year.
1BIIB had positive earnings in each of the past 5 years.
1BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.51%, 1BIIB belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
1BIIB has a Return On Equity of 8.84%. This is amongst the best in the industry. 1BIIB outperforms 83.33% of its industry peers.
With an excellent Return On Invested Capital value of 9.70%, 1BIIB belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 1BIIB is in line with the industry average of 12.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
The Profit Margin of 1BIIB (15.98%) is better than 84.62% of its industry peers.
In the last couple of years the Profit Margin of 1BIIB has declined.
The Operating Margin of 1BIIB (28.50%) is better than 88.46% of its industry peers.
1BIIB's Operating Margin has declined in the last couple of years.
1BIIB has a better Gross Margin (75.24%) than 67.95% of its industry peers.
1BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1BIIB is still creating some value.
The number of shares outstanding for 1BIIB has been increased compared to 1 year ago.
Compared to 5 years ago, 1BIIB has less shares outstanding
1BIIB has a better debt/assets ratio than last year.
2.2 Solvency
1BIIB has an Altman-Z score of 3.21. This indicates that 1BIIB is financially healthy and has little risk of bankruptcy at the moment.
1BIIB has a Altman-Z score of 3.21. This is in the better half of the industry: 1BIIB outperforms 78.21% of its industry peers.
1BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as 1BIIB would need 2.78 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.78, 1BIIB belongs to the best of the industry, outperforming 82.05% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that 1BIIB is not too dependend on debt financing.
The Debt to Equity ratio of 1BIIB (0.35) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.21 |
ROIC/WACC1.18
WACC8.21%
2.3 Liquidity
A Current Ratio of 2.72 indicates that 1BIIB has no problem at all paying its short term obligations.
1BIIB has a Current ratio (2.72) which is in line with its industry peers.
1BIIB has a Quick Ratio of 2.04. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
1BIIB has a Quick ratio (2.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
1BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
Measured over the past years, 1BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
1BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, 1BIIB will show a small growth in Earnings Per Share. The EPS will grow by 0.52% on average per year.
1BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.65% yearly.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.85, the valuation of 1BIIB can be described as reasonable.
Based on the Price/Earnings ratio, 1BIIB is valued cheaper than 93.59% of the companies in the same industry.
When comparing the Price/Earnings ratio of 1BIIB to the average of the S&P500 Index (26.15), we can say 1BIIB is valued rather cheaply.
1BIIB is valuated reasonably with a Price/Forward Earnings ratio of 10.56.
1BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 97.44% of the companies in the same industry.
1BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.85 | ||
| Fwd PE | 10.56 |
4.2 Price Multiples
1BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 91.03% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1BIIB indicates a rather cheap valuation: 1BIIB is cheaper than 92.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.69 | ||
| EV/EBITDA | 7.27 |
4.3 Compensation for Growth
The decent profitability rating of 1BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
No dividends for 1BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BIIB (11/13/2025, 7:00:00 PM)
143.15
+3.8 (+2.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap20.99B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target154.08 (7.64%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)5.12%
PT rev (3m)3.09%
EPS NQ rev (1m)-54.11%
EPS NQ rev (3m)-55.25%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.85 | ||
| Fwd PE | 10.56 | ||
| P/S | 2.4 | ||
| P/FCF | 10.69 | ||
| P/OCF | 9.85 | ||
| P/B | 1.33 | ||
| P/tB | 10.14 | ||
| EV/EBITDA | 7.27 |
EPS(TTM)14.53
EY10.15%
EPS(NY)13.55
Fwd EY9.47%
FCF(TTM)13.4
FCFY9.36%
OCF(TTM)14.53
OCFY10.15%
SpS59.6
BVpS107.8
TBVpS14.12
PEG (NY)N/A
PEG (5Y)N/A
Graham Number187.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.21%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / 1BIIB.MI FAQ
What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI.
What is the valuation status for 1BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.
Can you provide the profitability details for BIOGEN INC?
BIOGEN INC (1BIIB.MI) has a profitability rating of 7 / 10.
What is the earnings growth outlook for BIOGEN INC?
The Earnings per Share (EPS) of BIOGEN INC (1BIIB.MI) is expected to decline by -5.79% in the next year.